Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Femasys (NASDAQ: FEMY), a biomedical company focused on women's health, has announced plans for a public offering of common stock alongside a concurrent private placement. The company will grant underwriters a 30-day option to purchase up to an additional 15% of shares from the public offering. Current institutional stockholders, directors, and officers have shown interest in participating in the private placement.
Jones will serve as the sole book-running manager for the public offering and placement agent for the private placement. Femasys plans to use the proceeds for commercial expansion, product development, corporate purposes, capital expenditures, and working capital. The public offering will be made through a previously filed S-3 Registration Statement, while the private placement will rely on Securities Act exemptions.
Femasys (NASDAQ: FEMY), un'azienda biomedica specializzata nella salute femminile, ha annunciato l'intenzione di effettuare un offerta pubblica di azioni ordinarie insieme a un collocamento privato simultaneo. La società concederà agli underwriter un'opzione di 30 giorni per acquistare fino a un ulteriore 15% delle azioni offerte pubblicamente. Azionisti istituzionali attuali, membri del consiglio di amministrazione e dirigenti hanno manifestato interesse a partecipare al collocamento privato.
Jones agirà come unico responsabile del libro ordini per l'offerta pubblica e come agente di collocamento per il collocamento privato. Femasys prevede di utilizzare i proventi per espansione commerciale, sviluppo prodotto, scopi aziendali, spese in conto capitale e capitale circolante. L'offerta pubblica sarà effettuata tramite una dichiarazione di registrazione S-3 già depositata, mentre il collocamento privato si baserà sulle esenzioni previste dal Securities Act.
Femasys (NASDAQ: FEMY), una empresa biomédica enfocada en la salud de la mujer, ha anunciado planes para una oferta pública de acciones comunes junto con una colocación privada simultánea. La compañía otorgará a los suscriptores una opción de 30 días para comprar hasta un 15% adicional de las acciones de la oferta pública. Los accionistas institucionales actuales, directores y funcionarios han mostrado interés en participar en la colocación privada.
Jones será el único administrador principal del libro para la oferta pública y agente colocador para la colocación privada. Femasys planea utilizar los ingresos para expansión comercial, desarrollo de productos, fines corporativos, gastos de capital y capital de trabajo. La oferta pública se realizará a través de una Declaración de Registro S-3 previamente presentada, mientras que la colocación privada se basará en exenciones de la Ley de Valores.
Femasys (NASDAQ: FEMY)는 여성 건강에 중점을 둔 생명공학 회사로, 보통주 공개 모집과 동시에 진행되는 사모 배정을 계획하고 있다고 발표했습니다. 회사는 인수인에게 공개 모집 주식의 최대 15%를 추가로 매입할 수 있는 30일 옵션을 부여할 예정입니다. 현재 기관 투자자, 이사 및 임원들이 사모 배정에 참여할 의사를 보였습니다.
Jones는 공개 모집의 단독 주관사이자 사모 배정의 배정 대행사 역할을 맡습니다. Femasys는 수익금을 상업 확장, 제품 개발, 기업 목적, 자본 지출 및 운전자본에 사용할 계획입니다. 공개 모집은 이전에 제출된 S-3 등록 명세서를 통해 진행되며, 사모 배정은 증권법 면제를 기반으로 합니다.
Femasys (NASDAQ : FEMY), une société biomédicale spécialisée dans la santé des femmes, a annoncé son intention de réaliser une offre publique d'actions ordinaires accompagnée d'un placement privé simultané. La société accordera aux souscripteurs une option de 30 jours pour acheter jusqu'à 15 % supplémentaires des actions de l'offre publique. Les actionnaires institutionnels actuels, les administrateurs et les dirigeants ont manifesté leur intérêt pour participer au placement privé.
Jones agira en tant que gestionnaire principal unique pour l'offre publique et agent de placement pour le placement privé. Femasys prévoit d'utiliser les fonds pour l'expansion commerciale, le développement de produits, des fins corporatives, les dépenses en capital et le fonds de roulement. L'offre publique sera réalisée via une déclaration d'enregistrement S-3 déposée précédemment, tandis que le placement privé s'appuiera sur des exemptions prévues par le Securities Act.
Femasys (NASDAQ: FEMY), ein biomedizinisches Unternehmen mit Fokus auf Frauengesundheit, hat Pläne für ein öffentliches Angebot von Stammaktien zusammen mit einer gleichzeitigen Privatplatzierung angekündigt. Das Unternehmen gewährt den Underwritern eine 30-tägige Option zum Kauf von bis zu zusätzlichen 15 % der Aktien aus dem öffentlichen Angebot. Aktuelle institutionelle Aktionäre, Direktoren und Führungskräfte haben Interesse an der Teilnahme an der Privatplatzierung gezeigt.
Jones wird als alleiniger Bookrunner für das öffentliche Angebot und als Platzierungsagent für die Privatplatzierung fungieren. Femasys plant, die Erlöse für kommerziellen Ausbau, Produktentwicklung, Unternehmenszwecke, Investitionsausgaben und Betriebskapital zu verwenden. Das öffentliche Angebot erfolgt über eine zuvor eingereichte S-3-Registrierungserklärung, während die Privatplatzierung auf Ausnahmen des Wertpapiergesetzes basiert.
- Potential capital infusion to support commercial expansion and product development
- Show of confidence from existing institutional investors and insiders interested in private placement
- Multiple funding sources through both public offering and private placement
- Potential dilution for existing shareholders
- Uncertain offering terms and size create market uncertainty
- Additional shares could put downward pressure on stock price
Insights
Femasys plans to raise capital through stock offering and private placement, likely diluting existing shareholders while funding commercial expansion and product development.
Femasys (NASDAQ: FEMY) has announced plans to raise capital through both a public offering of common stock and a concurrent private placement. This dual-track financing approach suggests the company needs substantial capital infusion. The underwriters will have a 30-day option to purchase up to an additional 15% of shares, potentially increasing the size of the capital raise.
The company has indicated that existing institutional stockholders, directors, and officers have expressed interest in participating in the private placement portion, which may signal insider confidence but doesn't guarantee their participation. Jones is serving as the sole book-runner and placement agent, handling both transactions.
Femasys intends to use proceeds for commercial expansion, product development, and general corporate purposes including working capital. This suggests the company is prioritizing growth initiatives rather than merely addressing immediate operational needs.
For existing shareholders, this offering will almost certainly result in dilution of ownership as new shares enter the market. The lack of specified pricing and total shares to be offered leaves the magnitude of dilution uncertain. The company's need to raise capital through equity rather than debt financing may indicate limited borrowing capacity or a strategic preference to avoid interest obligations.
Investors should note that both transactions are subject to market conditions, with no guarantee of completion or final terms. The closing of each transaction is not contingent on the other, providing flexibility in execution but potentially creating uncertainty about the total capital raised.
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Femasys expects to grant the underwriters a 30-day option to purchase up to an additional
All of the securities in the public offering and private placement are being offered by Femasys. The public offering and private placement are subject to market conditions, and there can be no assurance as to whether or when the public offering and private placement may be completed, or as to the actual size or terms of the public offering and private placement. The closing of the public offering is not contingent on the private placement, and the closing of the private placement is not contingent on the public offering.
Jones is acting as sole book-running manager for the public offering and placement agent for the private placement.
Femasys intends to use the net proceeds from the public offering and private placement for expansion of commercial efforts, development of its products and product candidates, general corporate purposes, capital expenditures, working capital and general and administrative expenses.
The securities offered in the public offering are being offered by the Company pursuant to a Registration Statement on Form S-3 (File No. 333-266001) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on July 12, 2022. A preliminary prospectus supplement and the accompanying prospectus relating to the public offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the public offering may also be obtained from JonesTrading Institutional Services LLC, Attention: Equity Capital Markets, 325 Hudson Street, 6th Floor New York, New York 10013; email: ecm@jonestrading.com. The concurrent private placement of the securities will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and/or Regulation D thereunder. Accordingly, the securities issued in the concurrent private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release is neither an offer to sell, nor a solicitation of an offer to buy, any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale is unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
About Femasys
Femasys Inc. (NASDAQ: FEMY) is a biomedical company aiming to meet women’s needs worldwide by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s products currently marketed in the United States, include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect, and include, among others, statements regarding the completion of the public offering and the private placement, the satisfaction of customary closing conditions related to the public offering and the private placement and the anticipated use of proceeds therefrom. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: market and other conditions, our ability to develop and advance our FemBloc product candidates and programs into, and successfully initiate, enroll and complete, the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our FemBloc product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof and ability to raise sufficient capital for such model and plans; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
IR@femasys.com
Media Contact:
Media@femasys.com
FAQ
What is the purpose of Femasys (FEMY) stock offering and private placement?
How much additional stock can underwriters purchase in FEMY's public offering?
Who is managing Femasys (FEMY) public offering and private placement?
Are FEMY's public offering and private placement dependent on each other?
Who can participate in Femasys (FEMY) private placement?
